Swedish Orphan Biovitrum AB (publ) (BIOVF) Income Statement Analysis

See more : Scout Security Limited (SCT.AX) Income Statement Analysis – Financial Results

Complete financial analysis of Swedish Orphan Biovitrum AB (publ) (BIOVF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Swedish Orphan Biovitrum AB (publ), a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Swedish Orphan Biovitrum AB (publ) (BIOVF)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.sobi.com

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	22.12B	18.79B	15.53B	15.26B	14.25B	9.14B	6.51B	5.20B	3.23B	2.61B	2.18B	1.92B	1.91B	1.91B	1.30B	1.14B	1.26B	1.20B	936.61M	645.29M	1.66B	1.30B
Cost of Revenue	5.00B	4.78B	3.48B	3.23B	3.34B	2.42B	1.85B	1.55B	1.22B	1.06B	892.73M	882.78M	936.26M	685.70M	375.74M	264.66M	348.77M	293.81M	270.66M	248.32M	611.98M	596.87M
Gross Profit	17.13B	14.01B	12.05B	12.04B	10.91B	6.72B	4.66B	3.65B	2.01B	1.55B	1.28B	1.04B	974.57M	1.22B	921.23M	875.92M	907.66M	907.29M	665.95M	396.96M	1.05B	704.82M
Gross Profit Ratio	77.42%	74.58%	77.56%	78.87%	76.59%	73.57%	71.52%	70.14%	62.17%	59.37%	58.99%	54.10%	51.00%	64.04%	71.03%	76.80%	72.24%	75.54%	71.10%	61.52%	63.08%	54.15%
Research & Development	2.80B	2.35B	1.99B	1.59B	1.50B	1.09B	907.72M	777.59M	513.37M	500.49M	455.69M	401.65M	555.72M	479.80M	569.42M	670.56M	694.35M	650.35M	576.00M	534.70M	583.17M	568.73M
General & Administrative	10.16B	7.85B	6.29B	5.98B	0.00	0.00	1.28M	2.32M	3.46M	3.66M	3.38M	4.25M	804.46M	479.80M	193.30M	216.18M	77.38M	77.36M	151.23M	129.18M	114.99M	139.97M
Selling & Marketing	0.00	0.00	0.00	0.00	4.94B	2.51B	2.10B	1.78B	1.34B	1.03B	898.23M	961.14M	0.00	825.70M	109.61M	51.78M	43.72M	41.59M	38.66M	34.51M	37.18M	58.21M
SG&A	10.16B	7.85B	6.29B	5.98B	4.94B	2.51B	2.10B	1.78B	1.35B	1.04B	901.60M	965.39M	804.46M	1.31B	302.90M	267.96M	121.10M	118.95M	189.90M	163.69M	152.16M	198.17M
Other Expenses	105.00M	-32.00M	-30.00M	-2.00M	-16.00M	0.00	471.00K	1.70M	236.00K	781.00K	2.73M	8.84M	0.00	0.00	0.00	-380.10M	1.03M	266.00K	-402.49M	23.28M	-393.65M	22.67M
Operating Expenses	13.06B	10.17B	8.26B	7.57B	6.41B	3.60B	3.01B	2.55B	1.86B	1.53B	1.36B	1.36B	1.16B	1.14B	948.32M	11.73M	850.49M	802.81M	393.38M	339.54M	985.56M	660.71M
Cost & Expenses	18.06B	14.95B	11.74B	10.80B	9.75B	6.01B	4.86B	4.11B	3.08B	2.59B	2.25B	2.24B	2.10B	1.83B	1.32B	276.40M	1.20B	1.10B	664.05M	587.86M	1.60B	1.26B
Interest Income	27.00M	5.00M	419.00M	1.00M	5.00M	2.74M	1.22M	1.43M	2.93M	4.23M	4.49M	2.33M	10.50M	4.73M	28.60M	1.22M	3.01M	2.37M	1.58M	358.00K	924.00K	8.32M
Interest Expense	1.11B	458.00M	0.00	454.00M	241.00M	56.46M	63.97M	78.55M	54.71M	56.62M	60.41M	42.25M	62.73M	77.44M	12.34M	21.42M	450.00K	262.00K	49.43M	52.22M	36.84M	39.26M
Depreciation & Amortization	3.17B	2.27B	2.00B	2.02B	1.51B	484.57M	473.98M	440.71M	318.99M	581.55M	307.62M	454.30M	140.59M	175.40M	28.60M	-378.88M	70.49M	74.54M	-400.92M	23.63M	-392.72M	30.99M
EBITDA	7.23B	6.05B	5.72B	6.69B	6.08B	3.62B	2.08B	1.57B	461.39M	319.60M	240.26M	391.45M	-38.53M	165.20M	44.78M	-364.78M	155.46M	168.99M	-128.35M	-40.00M	-332.89M	75.10M
EBITDA Ratio	32.70%	32.99%	37.19%	41.26%	42.41%	39.64%	31.98%	30.03%	14.29%	25.69%	11.04%	6.30%	-9.32%	8.66%	3.45%	-30.21%	12.37%	17.76%	-13.70%	12.56%	-20.09%	5.77%
Operating Income	4.07B	3.81B	3.73B	4.82B	4.53B	3.12B	1.60B	1.13B	146.04M	-324.98M	-66.53M	-54.61M	-318.62M	-10.20M	16.17M	34.30M	55.12M	54.59M	272.56M	57.43M	59.84M	44.11M
Operating Income Ratio	18.38%	20.29%	24.04%	31.57%	31.81%	34.16%	24.58%	21.77%	4.52%	-12.47%	-3.06%	-2.84%	-16.67%	-0.53%	1.25%	3.01%	4.39%	4.54%	29.10%	8.90%	3.61%	3.39%
Total Other Income/Expenses	-1.11B	-492.00M	-438.00M	-601.00M	-286.00M	-40.00M	-73.69M	-50.16M	-57.83M	-336.58M	-56.88M	-24.97M	-52.23M	-82.17M	16.14M	-400.30M	23.87M	39.60M	-450.35M	-28.59M	-429.57M	-8.27M
Income Before Tax	2.95B	3.32B	3.30B	4.22B	4.25B	3.08B	1.53B	1.05B	87.69M	-318.57M	-123.42M	-105.09M	-370.85M	-92.40M	32.44M	-366.00M	78.99M	94.19M	-177.78M	28.84M	-369.73M	35.84M
Income Before Tax Ratio	13.35%	17.67%	21.22%	27.63%	29.81%	33.72%	23.54%	20.14%	2.72%	-12.22%	-5.67%	-5.46%	-19.41%	-4.85%	2.50%	-32.09%	6.29%	7.84%	-18.98%	4.47%	-22.31%	2.75%
Income Tax Expense	546.00M	683.00M	616.00M	972.00M	942.00M	663.94M	383.81M	238.91M	19.30M	-50.73M	-30.46M	-4.21M	-388.77M	12.00M	0.00	-30.64M	1.00K	1.52M	1.00M	-2.35M	-739.46M	1.00K
Net Income	2.41B	2.64B	2.68B	3.25B	3.30B	2.42B	1.15B	809.07M	68.39M	-267.83M	-92.96M	-100.88M	17.93M	-104.40M	32.44M	-335.36M	78.98M	92.67M	176.22M	-26.49M	369.73M	-35.85M
Net Income Ratio	10.89%	14.04%	17.25%	21.26%	23.19%	26.46%	17.64%	15.55%	2.12%	-10.27%	-4.27%	-5.25%	0.94%	-5.48%	2.50%	-29.40%	6.29%	7.72%	18.81%	-4.11%	22.31%	-2.75%
EPS	7.39	8.52	8.67	10.52	10.78	8.93	4.27	3.01	0.26	-1.01	-0.35	-0.38	0.07	-0.53	0.57	-3.00	0.78	0.90	1.73	-0.26	3.63	-0.35
EPS Diluted	7.39	8.44	8.62	10.41	10.72	8.93	4.25	3.01	0.26	-1.01	-0.35	-0.38	0.07	-0.52	0.57	-3.00	0.76	0.83	1.73	-0.26	3.63	-0.35
Weighted Avg Shares Out	325.98M	309.48M	308.90M	308.49M	306.38M	270.60M	269.02M	268.36M	267.28M	265.18M	265.27M	265.23M	242.12M	198.74M	56.42M	111.91M	101.82M	103.39M	101.82M	101.82M	101.82M	101.82M
Weighted Avg Shares Out (Dil)	325.97M	312.46M	310.73M	311.61M	308.35M	270.60M	270.00M	269.22M	267.28M	266.16M	265.27M	265.23M	242.12M	199.37M	56.97M	111.91M	104.54M	111.27M	101.82M	101.82M	101.82M	101.82M

Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)

November 11, 2024prnewswire.com

STOCKHOLM , Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"), to be held on Wednesday, 11 December 2024 at 09.00 at the...

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2024 Earnings Call Transcript

October 24, 2024seekingalpha.com

Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Guido Oelkers - CEO Henrik Stenqvist - CFO Lydia Abad-Franch - Head, R&D and CMO Armin Reininger - Senior Scientific Advisor...

Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases

August 8, 2024benzinga.com

Swedish Orphan Biovitrum AB (Sobi) SWOBY BIOVF and Apellis Pharmaceuticals, Inc. APLS on Thursday released topline data results from Phase 3 VALIANT study of systemic pegcetacoplan for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).